Journal Article

Tangshen formula improves diabetic nephropathy in STZ-induced diabetes rats fed with hyper-methionine by regulating the methylation status of kidney

Ma, Liang, Deng, GuoXiong, Li, Ping, Zheng, Jing, Tang, Han, Gao, Peng, Jiang, Yongwei, Cao, Yongtong, Zhao, Meimei, Li, Tianbao, Zhao, Hailing, Liu, Chengyin, Liu, Yi, Kong, Xiaomu

2024

Overview

Background The objective of this study was to examine and analyze differential methylation profiles in order to investigate the influence of hyper-methioninemia (HM) on the development of diabetic nephropathy (DN). Male Wistar rats, aged eight weeks and weighing 250–300 g, were randomly assigned into four groups: a control group (Healthy, n  = 8), streptozocin-induced rats (STZ group, n  = 8), HM + STZ group ( n  = 8), and the Tangshen Formula (TSF) treatment group (TSF group, n  = 8). Blood glucose levels and other metabolic indicators were monitored before treatment and at four-week intervals until 12 weeks. Total DNA was extracted from the aforementioned groups, and DNA methylation landscapes were analyzed via reduced representative bisulfite sequencing. Results Both the STZ group and HM + STZ group exhibited increased blood glucose levels and urinary albumin/creatinine ratios in comparison with the control group. Notably, the HM + STZ group exhibited a markedly elevated urinary albumin/creatinine ratio (411.90 ± 88.86 mg/g) compared to the STZ group (238.41 ± 62.52 mg/g). TSF-treated rats demonstrated substantial reductions in both blood glucose levels and urinary albumin/creatinine ratios in comparison with the HM + STZ group. In-depth analysis of DNA methylation profiles revealed 797 genes with potential therapeutic effects related to TSF, among which approximately 2.3% had been previously reported as homologous genes. Conclusion While HM exacerbates DN through altered methylation patterns at specific CpG sites, TSF holds promise as a viable treatment for DN by restoring abnormal methylation levels. The identification of specific genes provides valuable insights into the underlying mechanisms of DN pathogenesis and offers potential therapeutic targets for further investigation.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Albumin / Albumins - metabolism / Amino acids / Animals / Biomedical and Life Sciences / Biomedicine / Bisulfite / Blood Glucose / Blood levels / Blood sugar / CpG islands / Creatinine / Creatinine - metabolism / Creatinine - pharmacology / Creatinine - therapeutic use / Diabetes / Diabetes Mellitus / Diabetic nephropathies / Diabetic Nephropathies - chemically induced / Diabetic Nephropathies - drug therapy / Diabetic Nephropathies - genetics / Diabetic nephropathy / Differential methylation profiles / DNA Methylation / Epigenetics / Feeds / Gastric lavage / Gene Function / Genes / Genetic testing / Genomes / Glucose metabolism / Health aspects / Homocysteine / Human Genetics / Hyper-methionine / Kidney - metabolism / Kidneys / Laboratory animals / Male / Metabolism / Methionine / Methionine - metabolism / Methylation / Methylation patterns / Nephropathy / Pathogenesis / Racemethionine - metabolism / Racemethionine - pharmacology / Rats / Rats, Wistar / Streptozocin / Streptozocin - metabolism / Streptozocin - pharmacology / Streptozocin - therapeutic use / Sulfites / Tangshen formula / Therapeutic targets